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Abstract
Background: Therapeutic properties of ibogaine in the treatment of addiction are attracting both clinicians and patients to its use. Since ibogaine is not an 
authorized medicine, the quality of these products is not always known, increasing the probability of adverse reactions. Objective: This study collects different 
types of iboga-derived samples from treatment providers, vendors and online buyers to analyse their content. Methods: Analysis of iboga products (n = 16) 
was performed using gas chromatography and mass spectrometry methods (GC/MS). Products included Iboga root bark, Total Alkaloids (TA), Purified Total 
Alkaloids (PTA HCl), ibogaine hydrochloride (ibogaine HCl) and one Voacanga africana root bark. Results: The content of ibogaine was highly variable, ranging 
from 0.6% to 11.2% for products sold as iboga root bark, from 8.2% to 32.9% for products sold as TA, 73.7% for one sample sold as PTA and from 61.5% to 73.4% 
for products sold as ibogaine HCl. One sample did not show any iboga alkaloids. Other alkaloids and unknown substances were found in almost all samples. 
Discussion: The purity of iboga products is highly variable. These results should be taken into consideration by suppliers and users, especially regarding correct 
dosing to avoid overdose, as well as potential interactions with other substances.
Bouso JC et al. / Arch Clin Psychiatry. 2020;46(2):51-4
Keywords: Tabernanthe iboga, ibogaine, sample analysis, addiction treatment, harm reduction.
Address for correspondence: José Carlos Bouso. ICEERS Foundation. C/ Sepúlveda, 65, Despacho 2. 08015 Barcelona. Spain. Telephone/Fax: 0034 93 188 20 99. E-mail: jcbouso@iceers.org
Introduction
Ibogaine is a psychoactive alkaloid with hallucinogenic properties 
present in the root bark of Tabernanthe iboga, a tropical plant 
traditionally used in rites of passage and ethnomedicine in African 
countries such as Congo and Gabon1. Its anti-addictive properties 
were discovered serendipitously in the sixties by Howard Lotsof, who 
at that time was a heroin user and noticed that after using ibogaine his 
craving for heroin was significantly reduced. Since then, thousands of 
people have been treated with ibogaine to address drug dependence 
and/or for personal growth2. 
Pre-clinical research has demonstrated the anti-addictive 
properties of ibogaine in different animal species with reductions in 
self-administered morphine, cocaine, (meth)-amphetamines, alcohol 
and nicotine3. Ibogaine was also found to reduce or eliminate drug 
craving and withdrawal in humans in several case series and in clinical 
settings, but randomized trials are lacking4-7.
Indeed, the number of ibogaine clinics and ibogaine treatment 
providers has been increasing during the last few years. In 2008 it was 
estimated that 3,414 people used ibogaine, approximately a fourfold 
increase relative to the estimation of 857 from five years before8. 
From those 3,414 subjects, 68% used ibogaine for the treatment 
of drug addiction. In New Zealand, Australia and South Africa, 
ibogaine can be prescribed for the treatment of drug addiction (the 
legal status of ibogaine around the world can be found at: https://
www.ibogainealliance.org/ibogaine/law/). Most of the iboga that is 
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used in ibogaine clinics comes from Gabon, where unlicensed iboga 
exportation is forbidden. The lack of a regulated market results in 
a lack of quality control and patients may therefore be consuming 
ibogaine with unknown concentrations of active ingredients.
While ibogaine clinics are spreading around the world, accidents 
and fatalities have been increasing. By 2015 22 ibogaine-related 
deaths were reported9,10. Although ibogaine is considered a safe 
treatment when conducted under medical supervision11, many 
ibogaine providers offer ibogaine treatments outside of a medically 
controlled setting (for example, in hotel rooms). Furthermore, the 
purity of the ibogaine or iboga extracts used by treatment providers 
or self-administered by patients is frequently unknown, and. many 
clinics and private providers buy iboga/ibogaine from web-based 
suppliers without any quality control. This can increase the risks of 
adverse reactions and/or fatalities. 
In one of the fatalities, the hypotensional substance reserpine12 
was found in the blood of a man who died after ingesting ibogaine 
in Slovenia in 201113. Reserpine might potentiate the hypotensional 
effects of ibogaine, increasing the risks of cardiovascular toxicity. 
Furthermore, both reserpine and ibogaine are metabolized by 
CYP-2D614 and this specific drug interaction could increase the blood 
levels of ibogaine, increasing the risk of overdose. This is especially 
relevant when most of the time the concentration of iboga alkaloids in 
ibogaine samples is unknown. Because the ibogaine sample involved 
in the fatality was not analysed, it is unknown if it contained reserpine 
or if the person used any other herbal or pharmaceutical product 
containing it. In the same year, reserpine was found in ibogaine 
samples analysed in Slovenia12. Forensic analyses after ibogaine 
fatalities regularly show the presence of other drugs in the body15. 
Therefore, we performed this study to gain more insight into the 
purity and content of iboga samples available on the market, and to 




An advertisement was released through the website, newsletter 
and blog of the ICEERS Foundation (a non-profit organization 
that investigates the ethnobotany and therapeutic properties of 
iboga, ayahuasca, and cannabis) in July of 2013 (http://news.iceers.
org/2013/07/scientific-study-analysis-of-iboga/) asking treatment 
providers, vendors and buyers to send samples for analysis. We 
requested information about (A) the type of material (root bark, 
iboga extract, ibogaine hydrochloride (HCl), etc.); (B) the source 
(company, vendor, country, etc.); (C) date of purchase; (D) the 
expected percentage of ibogaine; (E) any information about abnormal 
effects experienced, potency, etc.; and (F) any additional information 
considered relevant. Requested samples could include: (A) pulverized 
root bark; (B) total alkaloids (TA) (solid extracts containing the 
alkaloids present in the root bark); (C) purified total alkaloids (PTA) 
(solid extracts containing the semi-purified alkaloids in salt form); 
and (D) “pure” ibogaine HCl. 
Samples preparation for GC/MS
GC/MS qualitative and quantitative analysis was carried by Energy 
Control, a Spanish non-governmental organization with extensive 
experience in drug analysis. Their methodology for the GC/MS 
analysis has been previously reported16.
The samples were prepared by dissolving 5.0 mg of each sample 
in 5.0 mL of methanol in glass vials. All vials were vortexed for 1 
minute and then sonicated for 15 minutes.
The substances were determined with gas chromatography 
coupled with mass spectrometry (Agilent 7890B gas chromatograph 
coupled to a 5977A quadrupole mass spectrometer detector; 
(Agilent; Santa Clara, CA, USA) at the Municipal Institute for 
Medical Research in Barcelona (IMIM – Hospital del Mar). The gas 
chromatograph was fitted with a G4513A auto-sampler injector. 
Samples were injected in split mode into a 30 meter, 0.25 mm i.d., 
0.25 mm film thickness 5% phenylmethylsilicone column (HP-5MS, 
Agilent Technologies). The oven temperature was initially maintained 
at 90 ºC for 2 min and programmed to reach 320 ºC at 20 ºC per min. 
It was finally maintained at 320 ºC for 9.5 min. The total run time was 
21.5 min. Insert liners packed with silanized glass wool were used. 
The injector and the interface were operated at 280 ºC. Helium was 
used as carrier gas at a flow rate of 1 mL/min. The mass spectrometer 
was operated in electron impact ionization mode at 70 eV. To 
confirm the mass spectra, two libraries were used: the Searchable 
Mass Spectral Library NIST/EPA/NIH Mass Spectral Library, Data 
Version: NIST 14 and the Searchable Mass Spectral Library Version 
2.3 (http://www.swgdrug.org/ms.htm). A GC/MS comparison of 
the samples with the analytical standards of ibogaine, ibogamine, 
and voacangine was also performed. Ibogaine and voacangine were 
provided by Phytostan Inc., Montreal, Quebec. Analysis certificates 
of Phytostan Inc. alkaloids have been performed by the laboratory of 
Martin Kuehne, Department of Chemistru, University of Vermont, 
Burlington, Vermont, verifying the high purities of those alkaloids15. 
Ibogamine was provided by REFORM Italia srd.
Data analysis
The moles of ibogaine HCl in the Phytostan reference sample per unit 
of signal intensity for the ibogaine peak were calculated based on the 
injected mass. The moles of each detected component in a sample 
were then calculated based on its signal intensity relative to that of 
the Phytostan sample times the moles in the Phytostan sample. The 
mass of each component was calculated using its molecular weight, 
accounting for salt form. The mass percent of each component was 
then obtained by dividing the mass of each component by the mass 
injected for the sample.
Results
Table 1 shows all the information gathered from the received samples. 
Source
We received 17 samples from five different known vendors during 
2013. Samples were submitted from nine different countries with date 
purchases from 2006 to 2013. One of the 17 samples was excluded 
due to suspected contamination during handling.
Samples
The 16 remaining samples used were: iboga root bark (n = 6), iboga 
TA extract (n = 5), iboga PTA HCl (n = 1), ibogaine HCl (n = 3), 
and Voacanga africana root bark (n = 1). Of the six samples of iboga 
root bark, one was sold as coming from a supplier in Cameroon. 
Alkaloid content
We were able to identify and quantify up to five different alkaloids 
from the samples (see Table 1). 
Table 2 shows means and ranges of iboga alkaloids found in the 
analysed samples. 
The alkaloid identification profile of the samples was similar 
for all products, except for one sample which did not contain any 
iboga alkaloid. The quantity of ibogaine was highly variable among 
the samples of each type of product and also among different types 
of products. High variability was especially worrying for the case 
of samples labelled as TA, which had the largest ibogaine variation. 
High variation in the content of ibogaine HCl samples was also 
found, possibly because some were actually PTA HCl based on all 
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Table 1. Description of the samples 




Iboga Root bark Unknown Australia Powder Light brown -- A: 0,6%
Iboga Root bark 2006 Netherlands Fine chopped bark Brown -- All unknown 
substances
Iboga Root bark 17/10/2012 New Zealand Powder Light brown 2-4% A: 11.2%
C: 0.7%
Iboga Root bark 11/04/2012 Canada Powder Brown -- A: 2.1%
C: 0,3%
Iboga Root bark 11/04/2012 Mexico Powder Light brown -- A: 9.9%
B: 0.1%
C: 0.6%




Iboga extract-PTA 11/04/2012 South Africa Powder Light brown 80% A: 73.7%
B: 4.7%
C: 6.1%
























Iboga extract-TA 11/10/2012 New Zealand Powder Dark brown Less than 10% (sold 















Ibogaine HCL Unknown Australia Powder White -- A: 73.4%
C: 2.1%
Ibogaine HCL 07/05/2013 Hawai USA Powder White -- A: 65.9%
C: 8.7%
Note. A: ibogaine; B: ibogaline; C: ibogamine; D: iboleutine; E: voacangine.
Table 2. Alkaloid summary 
Iboga Root Bark (n = 6) TA (n = 5) Ibogaine HCl (n = 3) PTA HCl (n = 1) V. africana (n = 1)
N Ave. Range N Ave. Range N Ave. Range N Ave. Range N Ave. Range
Ibogaine 5 6.2% 0.6%-11.2% 5 17.8% 8.2%-32.9% 3 67.0% 61.6%-73.4% 1 73.7% -- 1 0.6% --
Ibogaline 2 0.8% 0.1%-1.5% 5 0.69%% 0.2%-2.3% 1 7.2% -- 1 4.7% -- 0 -- --
Ibogamine 4 0.98% 0.3%-2.3% 5 4.3% 0.6%-16.4% 3 5.9% 2.1%-8.7% 1 6.1% -- 0 -- --
Voacangine 1 0.2% -- 5 0.25% 0.1%-0.6% 0 -- -- 0 -- -- 1 2.1% --
Iboleutine 0 -- -- 5 0.27% 0.1%-0.6% 0 -- -- 0 -- -- 0 -- --
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of them containing ibogamine and/or ibogaline in amounts similar 
to those for PTA HCl. 
The expected concentrations of ibogaine in the samples (which 
were rated by the senders) were below our results in two cases, with 
a large difference in iboga root bark from Cameroon, which had 
almost three times more ibogaine than expected. The remaining 
samples rated by the senders were above our results, with the largest 
discrepancy observed in the V. africana sample, which was expected 
to have a concentration of 5%-10% of voacangine but showed less 
than 2.1%.
We also found unknown substances in several samples which 
we were unable to identify.
Discussion and conclusions
This is the first report analysing iboga products from on-line suppliers. 
Results show a large diversity of iboga alkaloid content in all the 
different products (iboga root bark, iboga extracts and ibogaine HCl). 
This is especially meaningful for the ibogaine HCl samples, which are 
supposed to be purified. However, some ibogaine samples that have 
been used for scientific purposes in the past showed traces of ibogamine 
or ibogaline, even when the concentration of ibogaine was between 
95% and 99.6%17. Traces of ibogamine or ibogaline are to be expected 
in ibogaine isolated from the Tabernanthe iboga plant. During the 
analysis we also found substances other than iboga alkaloids in three 
of the samples, although we could not identify them. As noted above, 
we also found one sample that did not contain any iboga alkaloid. 
Also, two other samples contained less than 1% ibogaine. Low or zero 
concentrations of ibogaine should be of high concern. A recent report 
of a product sold as iboga bark was found to be Rauvolfia powder, 
which did not contain any iboga alkaloids and caused the death of the 
subject who used it thinking it was iboga root bark18.
The most relevant implication from these results is that ibogaine 
users are often not able to know the quality and purity of the 
purchased products when they come from on-line suppliers. Since 
many users and treatment providers obtain iboga/ibogaine for the 
treatment of addiction, they increase the potential risk of suffering 
side effects or adverse situations when they buy material of unknown 
quality from on-line suppliers. These adverse situations can include 
overdoses and fatalities15,19. 
The contents of alkaloids in the iboga plant have a large 
variation and depend on many variables such as subspecies, growing 
environment, harvesting time, conservation of the samples, etc. 
Our results could be a reflection of the variability of alkaloid 
concentrations in iboga-derived products and its relationship with 
dosing difficulties. Important cardiovascular effects are observed 
at doses often used in drug-detoxification. Ibogaine needs to be 
provided in low doses to ensure safety20 and because the variability 
within iboga products can be a source of serious adverse reactions, 
this is an issue that should be taken into account by practitioners. 
Given the high variability of ibogaine concentrations in iboga-
derived products, both users and providers should be careful during 
dose calculations. At the same time, harm reduction programs should 
include qualitative and quantitative drug analysis to avoid overdosing 
and related fatalities. Since this 2013 analysis, the manufacture of 
high-purity ibogaine HCl from Voacanga africana bark has increased, 
offering treatment providers with a another way to avoid the quality 
issues inherent in using bark or crude alkaloids for treatment.
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